Dakshidin Corporation, Inc. (DKSC) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $1.77M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerDakshidin Corporation, Inc. (DKSC) trades at $0.0004. Dakshidin Corporation, Inc. operates in the CBD/cannabis-based medical product sector, focusing on cultivation and online sales. The company manages distribution channels in retail, reselling, and direct sales markets. Market cap: $1.77M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for DKSC: DKSC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DKSC against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
DKSC: 1/2 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Dakshidin Corporation, Inc. (DKSC) Healthcare & Pipeline Overview
Dakshidin Corporation, Inc. is a CBD/cannabis-based medical product company involved in cultivation, online sales, and distribution channel management. Operating in the specialty and generic drug manufacturing industry, the company focuses on retail, reselling, and direct sales markets, with its headquarters in Miami and offices in Las Vegas.
What Is the Investment Thesis for DKSC?
Dakshidin Corporation, Inc. operates in the high-growth CBD/cannabis market, but its financial viability is questionable given its negative P/E ratio of -145.24. The company's success hinges on its ability to scale its cultivation operations, expand its online sales portal, and effectively manage its distribution channels. The company's beta of -1.23 suggests a negative correlation with the market, which could be seen as both a risk and an opportunity. Key value drivers include regulatory changes favoring cannabis use, expansion of product lines, and strategic partnerships. However, the company faces risks related to competition, regulatory uncertainty, and market volatility. Investors should closely monitor Dakshidin's revenue growth, cost management, and cash flow generation to assess its long-term potential.
Based on FMP financials and quantitative analysis
DKSC Key Highlights
Dakshidin Corporation, Inc. operates in the CBD/cannabis-based medical product sector.
- The company's P/E ratio is -145.24, indicating it is not currently profitable.
- Dakshidin's beta is -1.23, suggesting a negative correlation with the market.
- The company cultivates cannabis and operates an online sales portal for CBD products.
- Dakshidin manages distribution channel programs in retail, reselling, and direct sales markets.
Who Are DKSC's Competitors?
DKSC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AVCNF Avicanna Inc. | $0.08 | 0.00% | $10.6M | 529-signal |
| PLNH Planet 13 Holdings Inc. | $0.13 | -7.14% | $42.7M | 429-signal |
| DBCCF Decibel Cannabis Company Inc. | $1.27 | -3.39% | $49.0M | 459-signal |
| ZYBT Zhengye Biotechnology Holding Limited | $1.59 | +1.27% | $75.4M | 465-pillar |
| CWBHF Charlotte's Web Holdings, Inc. | $0.33 | -3.93% | $88.4M | 519-signal |
| AAWH Ascend Wellness Holdings, Inc. | $0.49 | +1.36% | $98.7M | 439-signal |
| BGM BGM Group Ltd. | $0.28 | +0.92% | $105M | 455-pillar |
| MEDXF Medexus Pharmaceuticals Inc. | $3.59 | -1.40% | $114M | 479-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are DKSC's Key Strengths?
Established presence in the CBD/cannabis market.
- Online sales portal for direct-to-consumer sales.
- Management of diverse distribution channels.
- Cultivation capabilities for supply chain control.
What Are DKSC's Weaknesses?
Negative P/E ratio indicating lack of profitability.
- Limited financial resources compared to larger competitors.
- Dependence on evolving regulatory environment.
- Unknown Disclosure Status on the OTC market.
What Could Drive DKSC Stock Higher?
DKSC catalyst: Potential changes in cannabis regulations at the state or federal level could create new market opportunities.
- Expansion of the company's online sales portal and marketing efforts to drive revenue growth.
- Strategic partnerships with established companies to expand market reach and distribution channels.
What Are the Key Risks for DKSC?
Financial-distress signal — its Altman Z-Score of -3.98 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Intense competition from other CBD/cannabis companies could erode market share and profitability.
- Evolving regulations and legal restrictions surrounding cannabis could negatively impact the company's operations.
- Fluctuations in cannabis prices and demand could affect revenue and profitability.
- Negative publicity and consumer perception of cannabis could harm the company's brand and reputation.
What Are the Growth Opportunities for DKSC?
- Expansion of Product Lines: Dakshidin can expand its product lines to include a wider range of CBD and cannabis-based medical products, such as edibles, topicals, and concentrates. Timeline: 1-2 years.
- Strategic Partnerships: Dakshidin can form strategic partnerships with established pharmaceutical companies, retailers, and distributors to expand its market reach and access new customer segments. Collaborations with pharmaceutical companies could facilitate the development and commercialization of cannabis-based therapies, while partnerships with retailers and distributors could enhance the company's distribution network. The timeline for establishing strategic partnerships is ongoing.
- Geographic Expansion: Dakshidin can expand its operations into new geographic markets, both domestically and internationally, as regulations surrounding cannabis and CBD evolve. The European cannabis market is expected to experience significant growth in the coming years, presenting opportunities for companies like Dakshidin to establish a presence in the region. Geographic expansion could involve establishing new cultivation facilities, distribution centers, or retail outlets. Timeline: 2-3 years.
- Online Sales Growth: Dakshidin can focus on growing its online sales channel through targeted marketing campaigns, enhanced website functionality, and improved customer service. The e-commerce market for CBD products is experiencing rapid growth, driven by increasing consumer adoption of online shopping and the convenience of purchasing CBD products from home. Investing in digital marketing and e-commerce infrastructure can help Dakshidin capture a larger share of the online CBD market. Timeline: Ongoing.
- Research and Development: Dakshidin can invest in research and development to develop innovative cannabis-based medical products and therapies. This could involve conducting clinical trials to evaluate the efficacy and safety of its products, as well as collaborating with research institutions to explore new applications for cannabis and CBD. Investing in R&D can help Dakshidin differentiate its products and establish a competitive advantage in the market. Timeline: Ongoing.
What Are DKSC's Competitive Advantages?
- Established online sales portal for CBD products.
- Management of distribution channels across multiple market segments.
- Cultivation capabilities providing control over supply chain.
- Early mover advantage in the CBD/cannabis market (founded in 2007).
What Does DKSC Do?
Dakshidin Corporation, Inc., formerly known as Avrada, Inc. until February 2007, operates as a CBD/cannabis-based medical product company. The company cultivates cannabis and manages an online sales portal for its CBD products, catering to the growing market for cannabis-derived health and wellness solutions. Dakshidin manages distribution channel programs across various market segments, including retail distribution, reselling, and direct sales, indicating a multi-faceted approach to market penetration. Headquartered in Miami, Florida, with additional offices in Las Vegas, Nevada, Dakshidin aims to establish a presence in key geographic markets. The company's focus on CBD and cannabis-based medical products positions it within a rapidly evolving sector, driven by increasing acceptance and legalization of cannabis for medical and recreational use in various jurisdictions. Dakshidin's business model encompasses cultivation, online retail, and distribution partnerships, reflecting an integrated approach to the cannabis value chain. The company seeks to capitalize on the expanding demand for CBD products, which are marketed for a range of health and wellness applications.
What Products and Services Does DKSC Offer?
- Cultivates cannabis for medical product development.
- Operates an online sales portal for CBD products.
- Manages distribution channel programs in the retail market.
- Manages distribution channel programs in the reselling market.
- Manages distribution channel programs in the direct sales market.
- Develops and markets CBD/cannabis-based medical products.
How Does DKSC Make Money?
- Cultivation of cannabis to produce raw materials.
- Online retail sales of CBD products directly to consumers.
- Distribution agreements with retailers and resellers.
- Direct sales through various channels.
What Industry Does DKSC Operate In?
Dakshidin Corporation, Inc. operates within the rapidly expanding CBD and cannabis-based medical product industry. This sector is characterized by evolving regulations, increasing consumer acceptance, and growing demand for cannabis-derived health and wellness products. The competitive landscape includes both established pharmaceutical companies exploring cannabis-based therapies and numerous smaller players focused on specific niches within the market. Dakshidin's success depends on its ability to navigate the regulatory environment, differentiate its products, and effectively compete with other companies such as ERBB, FITX, FTEG, GEATF, and GRCU.
Who Are DKSC's Key Customers?
- Individual consumers seeking CBD products for health and wellness.
- Retail stores that sell CBD products.
- Resellers who distribute CBD products to various markets.
- Patients seeking cannabis-based medical products (where legally permissible).
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 50 |
| 2026-08-26 | 50 |
| 2026-08-29 | 50 |
| 2026-09-01 | 50 |
| 2026-09-04 | 50 |
| 2026-09-07 | 50 |
| 2026-09-10 | 50 |
What changed?
The score has stayed at 50.
Over the same 18 days the stock moved -25.0%.
Financial Health
Dakshidin Corporation, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.98 places it in the distress zone, a signal of elevated financial risk.
DKSC Valuation & Market Position
With a $1.77M market cap, Dakshidin Corporation, Inc. sits in the micro-cap segment of the market.
Company Profile
Dakshidin Corporation, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Miami, US. The company is led by CEO Christopher Robin Haigh. DKSC has traded publicly since 2009.
DKSC Financials
Bull Case vs Bear Case
Bull Case
- Established presence in the CBD/cannabis market.
- Online sales portal for direct-to-consumer sales.
- Management of diverse distribution channels.
- Cultivation capabilities for supply chain control.
Bear Case
- Negative P/E ratio indicating lack of profitability.
- Limited financial resources compared to larger competitors.
- Dependence on evolving regulatory environment.
- Unknown Disclosure Status on the OTC market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
DKSC Latest News
No recent news available for DKSC.
DKSC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for DKSC.
Price Targets
Wall Street price target analysis for DKSC.
DKSC MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for DKSC; grades run from A+ (80-100) to F (below 30).
Leadership: Christopher Robin Haigh
CEO
Christopher Robin Haigh serves as the CEO of Dakshidin Corporation, Inc. Therefore, a comprehensive profile of his professional background cannot be constructed at this time. Further research would be required to ascertain his specific qualifications and experience in the healthcare or cannabis industries.
Track Record: Due to the limited information available, it is not possible to assess Christopher Robin Haigh's track record at Dakshidin Corporation, Inc. or in previous roles. Key achievements, strategic decisions, and company milestones under his leadership cannot be determined based on the provided data. Further information is needed to evaluate his performance and contributions to the company.
DKSC OTC Market Information
The OTC Other tier, also known as the Pink Sheets, represents the lowest tier of the OTC market. Companies in this tier often have limited or no reporting requirements, making it difficult for investors to obtain reliable information. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to stringent listing standards or regulatory oversight. This lack of regulation can lead to increased risks for investors, including potential fraud and manipulation. Companies in this tier may be distressed, early-stage, or have chosen not to meet the requirements for higher tiers.
- OTC Tier: OTC Other
- Limited or no financial reporting requirements.
- Potential for fraud and manipulation.
- Low trading volume and illiquidity.
- Lack of regulatory oversight.
- Higher risk of company failure.
- Verify the company's legal standing and registration.
- Attempt to obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's potential for future growth and profitability.
- Understand the risks associated with investing in OTC Other companies.
- Consult with a financial advisor before making any investment decisions.
- Company has been in operation since 2007.
- Operates in the growing CBD/cannabis market.
- Manages distribution channels across multiple market segments.
- Headquartered in Miami, Florida, with offices in Las Vegas, Nevada.
Dakshidin Corporation, Inc. Healthcare Stock: Key Questions Answered
Is DKSC a good stock?
Stock Expert AI does not rate DKSC buy, sell or hold. Dakshidin Corporation, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about DKSC stock?
There is currently no available analyst coverage or consensus on Dakshidin Corporation, Inc. (DKSC) stock. This lack of coverage may be due to the company's OTC listing and small market capitalization.
What are the key factors to evaluate for DKSC?
Evaluate DKSC on fundamentals, analyst consensus, and risk factors. Dakshidin Corporation, Inc. operates in the high-growth CBD/cannabis market, but its financial viability is questionable given its negative P/E ratio of -145.24. Not financial advice.
How frequently does DKSC data refresh on this page?
DKSC's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven DKSC's recent stock price performance?
Dakshidin Corporation, Inc. (DKSC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the CBD/cannabis market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DKSC overvalued or undervalued right now?
Dakshidin Corporation, Inc. (DKSC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of DKSC?
Yes, most major brokerages offer fractional shares of Dakshidin Corporation, Inc. (DKSC) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track DKSC's earnings and financial reports?
Dakshidin Corporation, Inc. (DKSC) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for DKSC earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for Dakshidin Corporation, Inc.
- OTC market stocks carry higher risk than exchange-listed stocks.